about
MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysisEuropean Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paragangliomaAldosterone synthase inhibition in humansThe Warburg effect is genetically determined in inherited pheochromocytomasAldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency.Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma.An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.Selection of patients for surgery for primary aldosteronism.CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism.Primary stenting for atherosclerotic renal artery stenosis.Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma.Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review.Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia).Outcomes of drug-based and surgical treatments for primary aldosteronism.Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.Diagnostic criteria for adrenal venous sampling.SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing.WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production.Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma.DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.LB01.11: PREVALENCE OF SECONDARY HYPERTENSION IN YOUNG HYPERTENSIVE ADULTS.Mast cell hyperplasia is associated with aldosterone hypersecretion in a subset of aldosterone-producing adenomas.Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma.Phaeochromocytomas and functional paragangliomas: clinical management.Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism.Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.[Endocrine hypertension].KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling.Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators.Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension.Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword.Hereditary angio-oedema: effective treatment with the progestogen-only pill in a young woman.Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.
P50
Q26747958-B9A2DEA9-B4A8-4D68-A4AD-5CB6249740FAQ26751465-4A8B00E7-BA1B-4ADA-B941-B28F04632EC7Q27016157-4B0ABBBE-DF14-411A-96A1-72BFE500B82BQ33504560-20C7E515-3391-4CF3-856A-8B81CCB36447Q33930728-5961AA1C-551B-4872-B122-318D7BA5DBDAQ34328209-D6582E34-CFCB-4EE2-8013-B03963C0AC2DQ35160825-4FDBE4AD-BA40-41F5-95AE-1319ED02910CQ36082463-E58A9FE4-C64C-4C8B-8B5A-463634699BBBQ36143337-07993D23-C1C8-41EC-8644-7D4319EE0513Q36477902-B73C20D1-2CB6-43BD-9CD0-A2096D20FC02Q37097169-65DE3DA8-8C43-43B2-8651-AEA5412FD5C7Q37604722-ADB7D1BB-66A7-4E2D-8F9A-F9C75B6D7FCDQ37757532-E3AD3B57-58D7-479C-8CD8-9E8C41933D41Q37986699-5A22936B-9050-4561-9087-C7FD8D5B4386Q37991222-AF33BB87-367F-4041-B35C-2BABDD7284BAQ38260261-ED2DD5CA-D3EA-4D35-9229-31CD03B1930EQ38266745-A26A717C-60D1-45C0-98AD-A8A68C7ECED0Q38373769-46F90FE6-FC9F-49DA-8B37-2E798906FA23Q38440045-296994D6-3666-4D2F-8101-5A90198DD451Q38675419-CBC7A77B-936D-4DFA-9E3B-FC0674F4B093Q38818901-6DD2B2DB-989E-4E51-AD96-653C37E0E123Q38864176-C2379E04-494F-4896-94EB-391EE59FEC3CQ38868568-7E894275-6486-4EEE-BD0E-37AE8716901DQ38869388-E31AA02A-8491-4F79-B8BA-8EEF889C4DD2Q39088795-D239E04F-9F7B-4294-9C7B-6AC1ECF5F3CEQ39179626-1EA78329-5F7F-4FE6-B3F2-35C425E88EC0Q40425821-C7305BF5-D5AC-4D8A-B1B9-9D27F7030777Q40807913-CF3DA064-56E0-4DD9-908C-5AE158B5B01AQ41564171-9D003107-9E51-4E50-8477-63DB561E993DQ42441172-0CDB3529-C10F-42B1-A12E-BA5D0EA103EAQ42790659-843F2B14-6D70-4D2D-9736-3B0E9D9A3E95Q42862052-ACE035EA-D514-49C7-8862-7DD3F8BD731AQ42908792-F815FFD4-7FF6-4A48-A7E7-1A83AEFEC6CCQ42950876-62CDA81F-35FA-41C0-9BDF-7139E2B33337Q44016115-225C0194-9F97-4276-9C4A-07CE4C663A95Q44697731-B7188A88-FDAF-4DDA-B91E-A49E95E58FFAQ44805596-878FBB70-810C-4AC2-AC2F-AEE304694DCBQ44962671-C22E5B8A-A9E3-46D7-9A0C-BF8BB59114A6Q45065384-E6C57EC9-B0AA-49D4-97D6-3DE9C8E43E25Q45219918-D0BF5DFC-B5D9-4936-9E5E-837285D8382A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laurence Amar
@ast
Laurence Amar
@en
Laurence Amar
@es
Laurence Amar
@nl
Laurence Amar
@sl
type
label
Laurence Amar
@ast
Laurence Amar
@en
Laurence Amar
@es
Laurence Amar
@nl
Laurence Amar
@sl
prefLabel
Laurence Amar
@ast
Laurence Amar
@en
Laurence Amar
@es
Laurence Amar
@nl
Laurence Amar
@sl
P1053
P-5278-2017
P106
P31
P3829
P496
0000-0003-3942-4276